Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03666143
Registration number
NCT03666143
Ethics application status
Date submitted
21/08/2018
Date registered
11/09/2018
Date last updated
24/03/2023
Titles & IDs
Public title
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.
Query!
Scientific title
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
CTR20181404
Query!
Secondary ID [2]
0
0
BGB-900-103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sitravatinib
Treatment: Drugs - Tislelizumab
Experimental: Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC -
Experimental: Anti-PD-1/PD-L1 antibody naïve NSCLC -
Experimental: Anti-PD-1/PD-L1 antibody refractory/resistant RCC -
Experimental: Metastatic or advanced RCC without prior systemic therapy -
Experimental: Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC -
Experimental: Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC -
Experimental: Anti-PD-1/PD-L1 antibody R/R melanoma -
Experimental: PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC -
Experimental: PD-L1 positive, naïve, advanced or metastatic, sq NSCLC -
Treatment: Drugs: Sitravatinib
120 mg orally once daily in combination with tislelizumab
Treatment: Drugs: Tislelizumab
200 mg IV once every 3 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with adverse events (AEs) and serious adverse events (SAEs) per NCI-CTCAE version 5.0
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
All AEs and SAEs will be reported until either 30 days after last dose of study drug(s) or initiation of new anticancer therapy, whichever occurs first. Immune-related should be reported until 90 days after the last dose of tislelizumab
Query!
Eligibility
Key inclusion criteria
1. Able to provide written informed consent and can understand and agree to comply with
the requirements of the study and the Schedule of Assessments
2. Age = 18 years on the day of signing the informed consent form (or the legal age of
consent in the jurisdiction in which the study is taking place)
3. At least 1 measurable lesion as defined by RECIST v1.1
4. Provide archival tumor tissue (formalin-fixed paraffin-embedded block [FFPE] with
tumor tissue or unstained slides), if available.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status = 1
6. Adequate hematologic and end-organ function
7. Patients with inactive/asymptomatic carrier, chronic, or active hepatitis B virus
(HBV) must have HBV deoxyribonucleic acid (DNA) < 500 IU/mL (or 2500 copies/mL) at
Screening
8. Females of childbearing potential must be willing to use a highly effective method of
birth control for the duration of the study, and = 120 days after the last dose of
study drugs and have a negative serum pregnancy test = 7 days of first dose of study
drugs
9. Non-sterile males must be willing to use a highly effective method of birth control
for the duration of the study and for = 120 days after the last dose of study drugs
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment.
2. Active leptomeningeal disease or uncontrolled brain metastasis.
3. Active autoimmune diseases or history of autoimmune diseases that may relapse.
4. Any active malignancy = 2 years
5. Any condition that required systemic treatment with either corticosteroids (> 10 mg
daily of prednisone or equivalent) or other immunosuppressive medication = 14 days
before first dose of study drugs
6. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled
diseases, including pulmonary fibrosis, acute lung diseases, etc.
8. Severe chronic or active infections (including tuberculosis infection, etc.) requiring
systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose
of study drugs
9. Known history of HIV infection
10. Patients with active hepatitis C infection.
11. Any major surgical procedure requiring general anesthesia = 28 days before first dose
of study drugs
12. Prior allogeneic stem cell transplantation or organ transplantation
13. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation,
or to any component of the container
14. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar
agents requiring therapeutic INR monitoring within 6 months before first dose of study
drugs
15. Concurrent participation in another therapeutic clinical trial
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/01/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
216
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Blacktown Cancer and Haematology Centre - Blacktown
Query!
Recruitment hospital [2]
0
0
ICON Cancer Foundation - South Brisbane
Query!
Recruitment hospital [3]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [4]
0
0
Monash Health - Melbourne
Query!
Recruitment hospital [5]
0
0
Nucleus Network - Melbourne
Query!
Recruitment hospital [6]
0
0
Linear Clinical Research Limited - Perth
Query!
Recruitment postcode(s) [1]
0
0
- Blacktown
Query!
Recruitment postcode(s) [2]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment postcode(s) [5]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
China
Query!
State/province [1]
0
0
Beijing
Query!
Country [2]
0
0
China
Query!
State/province [2]
0
0
Guangdong
Query!
Country [3]
0
0
China
Query!
State/province [3]
0
0
Jilin
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Shanghai
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Tianjin
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Zhejiang
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BeiGene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with
histologically or cytologically confirmed locally advanced or metastatic tumors including
non-squamous or squamous NSCLC, RCC, OC, or melanoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03666143
Query!
Trial related presentations / publications
Guo J, Zhou Q, Huang D, Yu X, Zhao J, Chu Q, Ma Z, Millward M, Gao B, Goh J, Markman B, Voskoboynik M, Gan H, Coward J, Chen C, Xiang X, Qui J, Xu Y, Yang L, Wu YL. A phase 1b study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors. Chinese Society of Clinical Oncology. 2019.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
BeiGene
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03666143
Download to PDF